# A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

> **NCT01631942** · PHASE1 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 4 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A
- Healthy

## Interventions

- **DRUG:** NNC172-2021

## Key facts

- **NCT ID:** NCT01631942
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06-26
- **Primary completion:** 2012-09-04
- **Final completion:** 2012-09-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** See detailed description
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01631942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01631942, "A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01631942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*